cervical cancer
Screening involves testing all women at risk for cervical cancer, most of whom will have no symptoms. It aims to detect pre-cancerous changes which, if left untreated, may develop into cancer.
Cervical cancer is the 12th most common cancer in women. Even if it is not the most common female cancer, it has the particularity of being aggressive and affecting young women more often. This cancer can be detected early and above all, be treated early without sequelae.
In the vast majority of cases, it is due to a persistent infection with human papillomavirus (HPV), a virus that is transmitted sexually.
When HPV settles in the cervix, it causes precancerous lesions which, in rare cases after ten to fifteen years of development, can become cancerous.
In France, there are approximately 3,100 cases of cancer of the cervix per year for every 1,000 deaths. In Corsica, the number of new cases is around thirty women.
cancer screening
of the cervix
Screening in practice in Corsica:
From February 2020, the Corsica Screening Center sends a letter to insured women aged 25 to 65 who reside in Corsica as well as a reminder if the sample is not taken within the year.
Provided with this invitation (or follow-up), the woman takes the sample from the doctor or midwife of her choice and, depending on the practice, the analysis laboratory (anatomopathology or biology) will send the results to the doctors and to the sampled woman.
This screening is for all women, including women vaccinated or not against the HPV virus. It also concerns pregnant women.
In case of delay or absence of the invitation letter,ask for your invite.
_cc781905-5cde-3194 -bb3b-136bad5cf58d_ _cc781905 -5cde-3194-bb3b-136bad5cf58d_ _cc781905-5cde-3194- bb3b-136bad5cf58d_ _cc781905- 5cde-3194-bb3b-136bad5cf58d_ _cc781905-5cde-3194-bb3b- 136bad5cf58d_ _cc781905-5cde- 3194-bb3b-136bad5cf58d_ _cc781905-5cde-3194 -bb3b-136bad5cf58d_ _cc781905 -5cde-3194-bb3b-136bad5cf58d_ _cc781905-5 cde-3194-bb3b-136bad5cf58d_ _cc781905-5cde-3194-bb3b -136bad5cf58d_ _cc781905-5cde -3194-bb3b-136bad5cf58d_ _cc781905-5cde-3194-bb3b- 136bad5cf58d_ _cc781905-5cde- 3194-bb3b-136bad5cf58d_ _cc781905-5cde-3194-bb3b-136bad5cf58 d_ _cc781905-5cde- 3194-bb3b-136bad5cf58d_ _cc781905-5cde-3194 -bb3b-136bad5cf58d_ _cc781905 -5cde-3194-bb3b-136bad5cf58d_ _cc781905-5cde-3194-bb 3b-136bad5cf58d_ _cc781905-94d5bad-36bad
An evolution of future screening:
If currently the smear is recommended every three years after 25 years, up to 65 years, the High Authority in Health recommends recently, a sample allowing the search for the virus at the level of the sample.
Unlike cytology, which looks at cell morphology, HPV testing looks for the presence of high-risk HPV virus DNA in women. The HAS recommends the use of the HPV test as first-line screening for cervical cancer from the age of 30. Like the cytological examination, it is carried out from a cervico-uterine sample.
In women over 30, it is significantly more effective in reducing the incidence of cervical cancer. In addition, in the event of a negative test, the use of the HPV test makes it possible to lengthen the interval between two screenings – going from every 3 years to every 5 years after 30 years. An update of the specifications should therefore evolve in 2020. We are also expecting the possibility for the women invited to use a self-sampling kit as is done in the context of colorectal cancer screening._cc781905-5cde- 3194-bb3b-136bad5cf58d_
And the vaccination?
Vaccination against human papillomaviruses (HPV) can prevent infections by the most frequent viruses, responsible for 70% to 90% of cancers of the cervix.
However, even vaccinated, it is essential to be screened by taking a smear every three years.
The vaccine is recommended for all young girls between the ages of 11 and 14. The vaccine is all the more effective as young girls have not yet been exposed to the risk of HPV infection.
Ask your attending physician for information on the modalities of the anti-HPV vaccine.
